Genentech enters agreement to develop autoimmune therapies

US-based biopharmaceutical company Parvus Therapeutics has entered into a collaboration and licensing agreement with Genentech, a subsidiary of Roche.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Tokyo court dismisses Genentech patent suit against Sandoz

4 June 2019 A Japanese court has dismissed a patent infringement lawsuit brought by Roche subsidiary Genentech against Sandoz, a division of Novartis.

Big Pharma

Genentech and Samsung Bioepis settle patent dispute over cancer biosimilar

5 July 2019 US-based biotechnology company Genentech, a subsidiary of Roche, has entered into a settlement agreement with Samsung Bioepis, ending all patent litigation between the two companies.

Americas

Genentech in $1.7bn immuno-oncology deal

27 February 2020 California-headquartered biotech Genentech has agreed to pay $30 million upfront to develop immuno-oncology therapies with UK-based Bicycle Therapeutics.

More on this story

Big Pharma

Tokyo court dismisses Genentech patent suit against Sandoz

4 June 2019 A Japanese court has dismissed a patent infringement lawsuit brought by Roche subsidiary Genentech against Sandoz, a division of Novartis.

Big Pharma

Genentech and Samsung Bioepis settle patent dispute over cancer biosimilar

5 July 2019 US-based biotechnology company Genentech, a subsidiary of Roche, has entered into a settlement agreement with Samsung Bioepis, ending all patent litigation between the two companies.

Americas

Genentech in $1.7bn immuno-oncology deal

27 February 2020 California-headquartered biotech Genentech has agreed to pay $30 million upfront to develop immuno-oncology therapies with UK-based Bicycle Therapeutics.

More on this story

Big Pharma

Tokyo court dismisses Genentech patent suit against Sandoz

4 June 2019 A Japanese court has dismissed a patent infringement lawsuit brought by Roche subsidiary Genentech against Sandoz, a division of Novartis.

Big Pharma

Genentech and Samsung Bioepis settle patent dispute over cancer biosimilar

5 July 2019 US-based biotechnology company Genentech, a subsidiary of Roche, has entered into a settlement agreement with Samsung Bioepis, ending all patent litigation between the two companies.

Americas

Genentech in $1.7bn immuno-oncology deal

27 February 2020 California-headquartered biotech Genentech has agreed to pay $30 million upfront to develop immuno-oncology therapies with UK-based Bicycle Therapeutics.

More features

Gilead scores win in fake HIV drug dispute

Polsinelli grows roster with ex-corporate counsel

‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird

Sandoz wins $137.2m payout for lost profits in generic launch

Sanofi signs global rights deal to develop rare cancer therapy

Unified Patent Court visualised: Cases, divisions, and classes in charts

WBD to merge with firm to create ‘powerhouse’ practice

‘Be prepared, and don’t assume at the UPC’: Christopher Stothers

Genentech enters agreement to develop autoimmune therapies

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features